{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:03:20Z","timestamp":1776391400176,"version":"3.51.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/132163\/2017"],"award-info":[{"award-number":["SFRH\/BD\/132163\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PD\/BD\/128377\/2017"],"award-info":[{"award-number":["PD\/BD\/128377\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04462\/2020"],"award-info":[{"award-number":["UIDB\/04462\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04462\/2020"],"award-info":[{"award-number":["UIDB\/04462\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04462\/2020"],"award-info":[{"award-number":["UIDB\/04462\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["739572"],"award-info":[{"award-number":["739572"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The current standard preclinical oncology models are not able to fully recapitulate therapeutic targets and clinically relevant disease biology, evidenced by the 90% attrition rate of new therapies in clinical trials. Three-dimensional (3D) culture systems have the potential to enhance the relevance of preclinical models. However, the limitations of currently available cellular assays to accurately evaluate therapeutic efficacy in these models are hindering their widespread adoption. We assessed the compatibility of the lactate dehydrogenase (LDH) assay in 3D spheroid cultures against other commercially available readout methods. We developed a standardized protocol to apply the LDH assay to ex vivo cultures, considering the impact of culture growth dynamics. We show that accounting for growth rates and background release levels of LDH are sufficient to make the LDH assay a suitable methodology for longitudinal monitoring and endpoint assessment of therapeutic efficacy in both cell line-derived xenografts (xenospheres) and patient-derived explant cultures. This method has the added value of being non-destructive and not dependent on reagent penetration or manipulation of the parent material. The establishment of reliable readout methods for complex 3D culture systems will further the utility of these tumor models in preclinical and co-clinical drug development studies.\n<\/jats:p>","DOI":"10.1038\/s41598-021-97894-0","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T10:04:13Z","timestamp":1631873053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Application of LDH assay for therapeutic efficacy evaluation of ex vivo tumor models"],"prefix":"10.1038","volume":"11","author":[{"given":"Megan C.","family":"Cox","sequence":"first","affiliation":[]},{"given":"Rita","family":"Mendes","sequence":"additional","affiliation":[]},{"given":"Fernanda","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Teresa F.","family":"Mendes","sequence":"additional","affiliation":[]},{"given":"Adelyn","family":"Zelaya-Lazo","sequence":"additional","affiliation":[]},{"given":"Kathleen","family":"Halwachs","sequence":"additional","affiliation":[]},{"given":"Julie J.","family":"Purkal","sequence":"additional","affiliation":[]},{"given":"In\u00eas A.","family":"Isidro","sequence":"additional","affiliation":[]},{"given":"Ana","family":"F\u00e9lix","sequence":"additional","affiliation":[]},{"given":"Erwin R.","family":"Boghaert","sequence":"additional","affiliation":[]},{"given":"Catarina","family":"Brito","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"97894_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"JA DiMasi","year":"2016","unstructured":"DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: New estimates of R&D costs. J. Health Econ. 47, 20\u201333 (2016).","journal-title":"J. Health Econ."},{"key":"97894_CR2","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.tips.2017.06.005","volume":"38","author":"Z Liu","year":"2017","unstructured":"Liu, Z., Delavan, B., Roberts, R. & Tong, W. Lessons learned from two decades of anticancer drugs. Trends Pharmacol. Sci. 38, 852\u2013872 (2017).","journal-title":"Trends Pharmacol. Sci."},{"key":"97894_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10555-013-9456-2","volume":"33","author":"B Thibault","year":"2014","unstructured":"Thibault, B., Castells, M., Delord, J. & Couderc, B. Ovarian cancer microenvironment: Implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev. 33, 17\u201339 (2014).","journal-title":"Cancer Metastasis Rev."},{"key":"97894_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.breast.2016.09.002","volume":"30","author":"K Velaei","year":"2016","unstructured":"Velaei, K., Samadi, N., Barazvan, B. & Rad, J. S. Tumor microenvironment-mediated chemoresistance in breast cancer. Breast 30, 92\u2013100 (2016).","journal-title":"Breast"},{"key":"97894_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.pan.2016.12.010","volume":"17","author":"P Dauer","year":"2018","unstructured":"Dauer, P., Nomura, A., Saluja, A. & Banerjee, S. Pancreatic cancer: Neighborhood matters. Pancreatology 17, 7\u201312 (2018).","journal-title":"Pancreatology"},{"key":"97894_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.bcp.2014.08.011","volume":"92","author":"DH Suh","year":"2014","unstructured":"Suh, D. H., Kim, H. S., Kim, B. & Song, Y. S. Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: A therapeutic implication. Biochem. Pharmacol. 92, 43\u201354 (2014).","journal-title":"Biochem. Pharmacol."},{"key":"97894_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-45397-2_1","volume-title":"Ex Vivo Engineering of the Tumor Microenvironment","author":"RW Jenkins","year":"2017","unstructured":"Jenkins, R. W. Introduction to ex vivo cancer models. In Ex Vivo Engineering of the Tumor Microenvironment (eds Aref, A. R. & Barbie, D.) 1\u201312 (Humana Press, 2017). https:\/\/doi.org\/10.1007\/978-3-319-45397-2_1."},{"key":"97894_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/adhm.201701174","volume":"7","author":"D Rodenhizer","year":"2018","unstructured":"Rodenhizer, D., Dean, T., D\u2019Arcangelo, E. & McGuigan, A. P. The current landscape of 3D in vitro tumor models: What cancer hallmarks are accessible for drug discovery?. Adv. Healthc. Mater. 7, 1\u201336 (2018).","journal-title":"Adv. Healthc. Mater."},{"key":"97894_CR9","doi-asserted-by":"publisher","first-page":"FSO190","DOI":"10.4155\/fsoa-2017-0003","volume":"3","author":"TG Meijer","year":"2017","unstructured":"Meijer, T. G., Naipal, K. A., Jager, A. & van Gent, D. C. Ex vivo tumor culture systems for functional drug testing and therapy response prediction. Futur. Sci. OA 3, FSO190 (2017).","journal-title":"Futur. Sci. OA"},{"key":"97894_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jconrel.2012.04.045","volume":"164","author":"G Mehta","year":"2012","unstructured":"Mehta, G., Hsiao, Y. A., Ingram, M., Luker, G. D. & Takayama, S. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J. Control Release 164, 192\u2013204 (2012).","journal-title":"J. Control Release"},{"key":"97894_CR11","doi-asserted-by":"publisher","first-page":"1600505","DOI":"10.1002\/biot.201600505","volume":"12","author":"VE Santo","year":"2017","unstructured":"Santo, V. E. et al. Drug screening in 3D in vitro tumor models: Overcoming current pitfalls of efficacy read-outs. Biotechnol. J. 12, 1600505 (2017).","journal-title":"Biotechnol. J."},{"key":"97894_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/diseases6040085","volume":"6","author":"J Gordon","year":"2018","unstructured":"Gordon, J., Brown, M. & Reynolds, M. Cell-based methods for determination of efficacy for candidate therapeutics in the clinical management of cancer. Diseases 6, 85 (2018).","journal-title":"Diseases"},{"key":"97894_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-56847-4","volume":"10","author":"S Abreu","year":"2020","unstructured":"Abreu, S. et al. Patient-derived ovarian cancer explants: Preserved viability and histopathological features in long-term agitation-based cultures. Sci. Rep. 10, 1\u201313 (2020).","journal-title":"Sci. Rep."},{"key":"97894_CR14","doi-asserted-by":"publisher","first-page":"e00149","DOI":"10.1002\/prp2.149","volume":"3","author":"J Foucquier","year":"2015","unstructured":"Foucquier, J. & Guedj, M. Analysis of drug combinations: Current methodological landscape. Pharmacol. Res. Perspect. 3, e00149 (2015).","journal-title":"Pharmacol. Res. Perspect."},{"key":"97894_CR15","doi-asserted-by":"publisher","first-page":"1600295","DOI":"10.1002\/biot.201600295","volume":"12","author":"K Halfter","year":"2017","unstructured":"Halfter, K. & Mayer, B. Bringing 3D tumor models to the clinic\u2014Predictive value for personalized medicine. Biotechnol. J. 12, 1600295 (2017).","journal-title":"Biotechnol. J."},{"key":"97894_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.addr.2014.06.004","volume":"79\u201380","author":"M Alemany-Ribes","year":"2014","unstructured":"Alemany-Ribes, M. & Semino, C. E. Bioengineering 3D environments for cancer models. Adv. Drug Deliv. Rev. 79\u201380, 40\u201349 (2014).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"97894_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jbiotec.2015.02.007","volume":"205","author":"V Charwat","year":"2015","unstructured":"Charwat, V. et al. Potential and limitations of microscopy and Raman spectroscopy for live-cell analysis of 3D cell cultures. J. Biotechnol. 205, 70\u201381 (2015).","journal-title":"J. Biotechnol."},{"key":"97894_CR18","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1007\/s00432-016-2198-0","volume":"142","author":"JM Huber","year":"2016","unstructured":"Huber, J. M. et al. Evaluation of assays for drug efficacy in a three-dimensional model of the lung. J. Cancer Res. Clin. Oncol. 142, 1955\u20131966 (2016).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"97894_CR19","doi-asserted-by":"publisher","first-page":"16645","DOI":"10.1038\/s41598-017-16622-9","volume":"7","author":"A-L Bulin","year":"2017","unstructured":"Bulin, A.-L., Broekgaarden, M. & Hasan, T. Comprehensive high-throughput image analysis for therapeutic efficacy of architecturally complex heterotypic organoids. Sci. Rep. 7, 16645 (2017).","journal-title":"Sci. Rep."},{"key":"97894_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm.3522","volume":"20","author":"M Kleppe","year":"2014","unstructured":"Kleppe, M. & Levine, R. L. Tumor heterogeneity confounds and illuminates: Assessing the implications. Nat. Med. 20, 342\u2013344 (2014).","journal-title":"Nat. Med."},{"key":"97894_CR21","first-page":"105","volume":"1805","author":"A Marusyk","year":"2010","unstructured":"Marusyk, A. & Polyak, K. Tumor heterogeneity: Causes and consequences. Biochim. Biophys. Acta 1805, 105\u2013117 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"97894_CR22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila, M. R. & de Sauvage, F. J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346\u2013354 (2013).","journal-title":"Nature"},{"key":"97894_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep28951","volume":"6","author":"K Stock","year":"2016","unstructured":"Stock, K. et al. Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery. Sci. Rep. 6, 1\u201315 (2016).","journal-title":"Sci. Rep."},{"key":"97894_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-1-62703-290-2_7","volume":"979","author":"FK-M Chan","year":"2013","unstructured":"Chan, F.K.-M., Moriwaki, K. & De Rosa, M. J. Detection of necrosis by release of lactate dehydrogenase (LDH) activity. Methods Mol. Biol. 979, 65\u201370 (2013).","journal-title":"Methods Mol. Biol."},{"key":"97894_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-14326-8","volume":"7","author":"KF Goliwas","year":"2017","unstructured":"Goliwas, K. F. et al. Methods to evaluate cell growth, viability, and response to treatment in a tissue engineered breast cancer model. Sci. Rep. 7, 1\u201314 (2017).","journal-title":"Sci. Rep."},{"key":"97894_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/002215540505300104","volume":"53","author":"PCW De Hamer","year":"2005","unstructured":"De Hamer, P. C. W., Jonker, A., Leenstra, S., Ruijter, J. M. & Van Noorden, C. J. F. Quantification of viability in organotypic multicellular spheroids of human malignant glioma using lactate dehydrogenase activity: A rapid and reliable automated assay. J. Histochem. Cytochem. 53, 23\u201334 (2005).","journal-title":"J. Histochem. Cytochem."},{"key":"97894_CR27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/bit.260460408","volume":"46","author":"JL Moreira","year":"1995","unstructured":"Moreira, J. L., Alves, P. M., Aunins, J. G. & Carrondo, M. J. T. Hydrodynamic effects on BHK cells grown as suspended natural aggregates. Biotechnol. Bioeng. 46, 351\u2013360 (1995).","journal-title":"Biotechnol. Bioeng."},{"key":"97894_CR28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1472-6750-9-82","volume":"9","author":"M Serra","year":"2009","unstructured":"Serra, M., Brito, C., Costa, E. M., Sousa, M. F. Q. & Alves, P. M. Integrating human stem cell expansion and neuronal differentiation in bioreactors. BMC Biotechnol. 9, 82 (2009).","journal-title":"BMC Biotechnol."},{"key":"97894_CR29","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrc.2016.91","volume":"16","author":"L Zitvogel","year":"2016","unstructured":"Zitvogel, L., Pitt, J. M., Daill\u00e8re, R., Smyth, M. J. & Kroemer, G. Mouse models in oncoimmunology. Nat. Rev. Cancer 16, 759\u2013773 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"97894_CR30","first-page":"3","volume":"7","author":"DK Mishra","year":"2012","unstructured":"Mishra, D. K. et al. Human lung cancer cells grown in an ex vivo 3D lung model produce matrix metalloproteinases not produced in 2D culture. PLoS ONE 7, 3\u201312 (2012).","journal-title":"PLoS ONE"},{"key":"97894_CR31","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1177\/2472555219830087","volume":"24","author":"TH Booij","year":"2019","unstructured":"Booij, T. H., Price, L. S. & Danen, E. H. J. 3D cell-based assays for drug screens: Challenges in imaging, image analysis, and high-content analysis. SLAS Discov. 24, 615\u2013627 (2019).","journal-title":"SLAS Discov."},{"key":"97894_CR32","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1021\/acsbiomaterials.5b00172","volume":"1","author":"MC Cox","year":"2015","unstructured":"Cox, M. C., Reese, L. M., Bickford, L. R. & Verbridge, S. S. Toward the broad adoption of 3D tumor models in the cancer drug pipeline. ACS Biomater. Sci. Eng. 1, 877\u2013894 (2015).","journal-title":"ACS Biomater. Sci. Eng."},{"key":"97894_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3390\/ijms19010181","volume":"19","author":"J Hoarau-V\u00e9chot","year":"2018","unstructured":"Hoarau-V\u00e9chot, J., Rafii, A., Touboul, C. & Pasquier, J. Halfway between 2D and animal models: Are 3D cultures the ideal tool to study cancer-microenvironment interactions?. Int. J. Mol. Sci. 19, 181 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"97894_CR34","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/ijms20040840","volume":"20","author":"C Roma-Rodrigues","year":"2019","unstructured":"Roma-Rodrigues, C., Mendes, R., Baptista, P. & Fernandes, A. Targeting tumor microenvironment for cancer therapy. Int. J. Mol. Sci. 20, 840 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"97894_CR35","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nmeth.3853","volume":"13","author":"M Hafner","year":"2016","unstructured":"Hafner, M., Niepel, M., Chung, M. & Sorger, P. K. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13, 521\u2013527 (2016).","journal-title":"Nat. Methods"},{"key":"97894_CR36","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/annonc\/mdg490","volume":"14","author":"C Mita","year":"2003","unstructured":"Mita, C. et al. Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies. Ann. Oncol. 14, 1776\u20131782 (2003).","journal-title":"Ann. Oncol."},{"key":"97894_CR37","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1023\/A:1008387019062","volume":"9","author":"LL Siu","year":"1998","unstructured":"Siu, L. L. et al. Activity of (-)-2\u2019-deoxy-3\u2019-oxacytidine (BCH-4556) against human tumor colony-forming units. Ann. Oncol. 9, 885\u2013891 (1998).","journal-title":"Ann. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97894-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97894-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97894-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T15:40:32Z","timestamp":1670082032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97894-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["97894"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-97894-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"assertion":[{"value":"19 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MCC, AZ, KH, JP, and ERB were employed by AbbVie when the data were generated. JP and ERB hold AbbVie stock. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18571"}}